COBRE-DIABETES

糖尿病

• 批准号: 10399857
• 负责人: MARIANA GERSCHENSON
• 金额: $ 23.18万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10399857
• 关键词: Acute; Address; Administrative Supplement; Animals; Bioluminescence; Blood; Blood Volume; Blood gas; Centers of Research Excellence; Chemistry; Clinical; Contract Services; Core Facility; Diabetes Mellitus; Diagnosis; Dose; Electrolytes; Equipment; Evaluation; Fluorescence; Fostering; Funding; Funding Opportunities; Goals; Growth; Hawaii; Hematocrit procedure; Hemoglobin; Individual; Infrastructure; Investigation; Longitudinal Studies; Metabolic; Minority Groups; Modernization; Mus; National Institute of General Medical Sciences; Phase; Population; Prevention; Renal function; Research; Research Personnel; Resources; Roentgen Rays; Services; System; Technology; Testing; Universities; Vision; career development; cost; equipment acquisition; health disparity; imaging system; improved; in vivo; in vivo imaging system; medical schools; operation; rapid test; response

PROJECT SUMMARY/ABSTRACT This application is for a supplement to support a Phase I Center of Biomedical Research Excellence (COBRE) at the University of Hawaii (UH) on Diabetes (1P20GM113134-04) in response to funding opportunity NOT- GM-21-029, “Administrative Supplements for Equipment Purchases for NIGMS-funded Center and Core Facilities”. The COBRE-Diabetes has developed a Resource Core dedicated to supporting career development for young investigators and to foster diabetes-related research in the state, which is acutely needed. It is estimated that a third of the State’s population will be living with diabetes by the year 2050. The COBRE-Diabetes Resource Core goal is to establish a new and easily accessible modern infrastructure to support investigations in the mechanisms, diagnosis, prevention, and/or treatment of diabetes to address health disparities in the minority populations in Hawaii. Our unique aim is to Maintain the growth and enhance the sustainability of Resource Core. With this proposal, we will optimize our core capacity in order to continue capacity improvement that has been successfully initiated in the first Phase of COBRE-Diabetes funding. In order to accomplish this objective, we request funding for the acquisition of two new pieces of equipment. We hope to replace an existing obsolete Xenogen Vivo Vision IVIS Lumina Imaging system with an IVIS Lumina XRMS in vivo imaging system. This is equipment offers cutting edge in vivo fluorescence and bioluminescence technology combined with low dose 2D X-ray allowing for non-invasive and precise metabolic analyses. This will give us an expanded capacity with multiple animals to perform longitudinal studies. The second equipment is an i-STAT clinical blood analyzer that operates with the advanced technology of single- use i-STAT test cartridges offering a wide array of tests on a single platform, including rapid tests for electrolytes, chemistries, blood gases, hematocrit and hemoglobin or the fast evaluation of metabolic status and renal function. This system uses minimal blood volumes, which will not require animal (mouse) sacrifice. Blood analyses are currently done using individual and dedicated kits that is laborious or contracting services outside of the University. There are many projects ongoing in the DRC that can best be performed in Hawaii. Our distance from US mainland requires that we develop a fundamental repertoire of Core services for diabetes research with COBRE resources. The Dean of the Medical School has committed to provide institutional support to cover the cost of operation for three years after the purchase of these equipment.

项目摘要/摘要 本申请是对第一阶段生物医学研究卓越中心(COBRE)的补充 在夏威夷大学(UH)糖尿病(1P20GM113134-04)上，回应资助机会不- GM-21-029，《NIGMS资助中心和核心设备采购的行政补充资料》 设施“。科布雷-糖尿病开发了一个致力于支持职业发展的资源核心 对于年轻的研究人员，并在该州促进糖尿病相关研究，这是迫切需要的。它是 据估计，到2050年，该州三分之一的人口将患有糖尿病。 科布雷-糖尿病资源的核心目标是建立一个新的、易于访问的现代基础设施，以 支持对糖尿病的机制、诊断、预防和/或治疗进行研究，以解决 夏威夷少数民族人口的健康差距。我们独特的目标是保持增长和 增强资源核心的可持续性。有了这一提议，我们将按照顺序优化我们的核心能力 继续在COBRE-糖尿病的第一阶段成功启动的能力改进 资金问题。为了实现这一目标，我们请求提供资金，用于购买两件新的 设备。我们希望将现有的过时的Xenogen Vivo Vision IVIS Lumina成像系统替换为 IVIS Lumina XRMS活体成像系统。这是一种提供尖端在体荧光和 生物发光技术结合低剂量2D X射线实现无创、精确的代谢 分析。这将使我们有更大的能力进行多个动物进行纵向研究。这个 第二台设备是I-STAT临床血液分析仪，采用先进的单机和单机技术运行。 使用I-STAT测试盒，在单个平台上提供多种测试，包括快速测试 电解质、化学成分、血气、红细胞压积和血红蛋白或新陈代谢状态的快速评估 和肾功能。该系统使用最小的血量，不需要牺牲动物(老鼠)。 目前，血液分析是使用费力或承包服务的个人专用试剂盒进行的 在大学外面。在刚果民主共和国有许多正在进行的项目，最好是在夏威夷执行。 我们与美国大陆的距离要求我们为以下方面开发基本的核心服务 利用Cobre资源进行糖尿病研究。医学院院长承诺提供 机构支助，以支付购买这些设备后三年的运作费用。

项目成果

The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction.

• DOI: 10.3390/cells11091399
• 发表时间: 2022-04-20
• 期刊: CELLS
• 影响因子: 6
• 作者: Komai, Kyoko;Kawasaki, Nicholas K.;Higa, Jason K.;Matsui, Takashi
• 通讯作者: Matsui, Takashi

Bicuspid and unicuspid aortic valves: Different phenotypes of the same disease? Insight from the GenTAC Registry.

二叶式和单叶式主动脉瓣：同一疾病的不同表型？

• DOI: 10.1111/chd.12520
• 发表时间: 2017
• 期刊: Congenital heart disease
• 影响因子: 0.3
• 作者: Krepp,JosephM;Roman,MaryJ;Devereux,RichardB;Bruce,Adrienne;Prakash,SiddharthK;Morris,ShaineA;Milewicz,DiannaM;Holmes,KathrynW;Ravekes,William;Shohet,RalphV;Pyeritz,ReedE;Maslen,CherylL;Kroner,BarbaraL;Eagle,KimA;Pre
• 通讯作者: Pre

Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C.

• DOI: 10.1371/journal.pone.0261563
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Gojanovich GS;Jacobson DL;Broadwell C;Karalius B;Kirmse B;Geffner ME;Jao J;Van Dyke RB;McFarland EJ;Silio M;Crain M;Gerschenson M;Pediatric HIV/AIDS Cohort Study
• 通讯作者: Pediatric HIV/AIDS Cohort Study

The effects of Tel2 on cardiomyocyte survival.

Tel2 对心肌细胞存活的影响。

• DOI: 10.1016/j.lfs.2019.116665
• 发表时间: 2019
• 期刊: Life sciences
• 影响因子: 6.1
• 作者: Yorichika,Naaiko;Baba,Yuichi;Shimada,BrianaK;Thakore,Manoj;Wong,SharonM;Kobayashi,Motoi;Higa,JasonK;Matsui,Takashi
• 通讯作者: Matsui,Takashi

The ABCC6 Transporter: A New Player in Biomineralization.

• DOI: 10.3390/ijms18091941
• 发表时间: 2017-09-11
• 期刊: International journal of molecular sciences
• 影响因子: 5.6
• 作者: Favre G;Laurain A;Aranyi T;Szeri F;Fulop K;Le Saux O;Duranton C;Kauffenstein G;Martin L;Lefthériotis G
• 通讯作者: Lefthériotis G